RT Journal Article
SR Electronic
T1 Impact of mass testing during an epidemic rebound of SARS-CoV-2: A modelling study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.08.20246009
DO 10.1101/2020.12.08.20246009
A1 Bosetti, Paolo
A1 Tran Kiem, Cécile
A1 Yazdanpanah, Yazdan
A1 Fontanet, Arnaud
A1 Lina, Bruno
A1 Colizza, Vittoria
A1 Cauchemez, Simon
YR 2020
UL http://medrxiv.org/content/early/2020/12/16/2020.12.08.20246009.abstract
AB We used a mathematical model to evaluate the impact of mass testing in the control of SARS-CoV-2. Under optimistic assumptions, we find that one round of mass testing may reduce daily infections by up to 20-30%. As a consequence, very frequent testing would be required to control a quickly growing epidemic if other control measures were to be relaxed. Mass testing is most relevant when epidemic growth remains limited, thanks to a combination of interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge financial support from the Investissement d'Avenir program, the Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases program (grant ANR-10-LABX-62-IBEID), Santé Publique France, the INCEPTION project (PIA/ANR-16-CONV-0005), and the European Union's Horizon 2020 research and innovation program under grants 101003589 (RECOVER) and 874735 (VEO), AXA. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data referred in the manuscript.